Clinical Trials
| Cancer Type: Renal | |
| Description: The BeST Trial: A Randomized Phase II Study of VEGF, RAF kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma | |
| Entity Approving The Trial: Eastern Cooperative Oncology Group (ECOG) |
|
| Phase: II | |
| Site-Wide Accrual Goal: 360 | |
| Related Files | |
| No related files found. | |
| Related Links | |
| No related links found. |
 |
 |
|
